← Product Code [HSX](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/HSX) · K232114

# TRIBRID® Unicompartmental Knee System (K232114)

_Kyocera Medical Technologies, Inc. · HSX · Apr 4, 2024 · Orthopedic · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/HSX/K232114

## Device Facts

- **Applicant:** Kyocera Medical Technologies, Inc.
- **Product Code:** [HSX](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/HSX.md)
- **Decision Date:** Apr 4, 2024
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 888.3520
- **Device Class:** Class 2
- **Review Panel:** Orthopedic
- **Attributes:** Therapeutic

## Intended Use

The Kyocera TRIBRID® Unicompartmental Knee System is indicated for use in patients with the following: - Painful and disabled knee joint resulting from osteoarthritis, or idiopathic osteonecrosis, of . either the medial or lateral compartments. - Correction of varus, valgus, or posttraumatic deformity. . - As an alternative to tibial osteotomy in patients with unicompartmental NIDJD disease. . - Revision procedures where other treatments or devices have failed. ● This device is intended for cemented use only.

## Device Story

Partial knee replacement system; includes femoral and tibial components; femoral baseplates (CoCrMo alloy); tibial implants (Ti6Al4V alloy); tibial bearing inserts (UHMWPE). Used in orthopedic surgery for primary or revision knee arthroplasty. Components implanted via bone cement to replace damaged joint surfaces. Provides structural support to restore joint function and correct deformities. Surgeon selects appropriate size/design based on patient anatomy. Benefits include pain relief and improved mobility for patients with unicompartmental knee disease.

## Clinical Evidence

Bench testing only. Testing included baseplate fatigue (ASTM F3140-17), intrinsic stability, modular disassembly (ASTM F1814, ASTM F2083), femoral component durability (ASTM F3210-22), range of motion (ASTM F2083), and simulated wear (ISO 14243-3). Results demonstrate sufficient strength and performance equivalent to predicate.

## Technological Characteristics

Materials: CoCrMo alloy (femoral baseplates), Ti6Al4V alloy (tibial implants), UHMWPE (tibial inserts). Cemented fixation. Standards: ASTM F3140-17, ASTM F1814, ASTM F2083, ASTM F3210-22, ISO 14243-3. Mechanical prosthesis; no software or electronic components.

## Regulatory Identification

A knee joint femorotibial metal/polymer non-constrained cemented prosthesis is a device intended to be implanted to replace part of a knee joint. The device limits minimally (less than normal anatomic constraints) translation in one or more planes. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral condylar resurfacing component or components made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components made of ultra-high molecular weight polyethylene and are intended for use with bone cement (§ 888.3027).

## Predicate Devices

- JOURNEY II Unicompartmental Knee ([K190085](/device/K190085.md))

## Reference Devices

- MOTO™ Lateral Partial Knee System ([K183029](/device/K183029.md))
- Renovis A200 PS Knee System ([K190122](/device/K190122.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left, there is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

April 4, 2024

Kyocera Medical Technologies, Inc. % Nathan Wright Engineer & Regulatory Specialist Empirical Technologies 4628 Northpark Drive Colorado Springs, CO 80918

## Re: K232114

Trade/Device Name: TRIBRID® Unicompartmental Knee System Regulation Number: 21 CFR 888.3520 Regulation Name: Knee Joint Femorotibial Metal/Polymer Non-Constrained Cemented Prosthesis Regulatory Class: Class II Product Code: HSX Dated: March 7, 2024 Received: March 8, 2024

### Dear Nathan Wright:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

{1}------------------------------------------------

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Peter G. Allen -S Allen -S
Digitally signed by Peter G.
Date: 2024.04.04 16:21:20
-04'00'

For: Lixin Liu, PhD Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known)

#### K232114

Device Name

### TRIBRID® Unicompartmental Knee System

### Indications for Use (Describe)

The Kyocera TRIBRID® Unicompartmental Knee System is indicated for use in patients with the following:

- Painful and disabled knee joint resulting from osteoarthritis, or idiopathic osteonecrosis, of . either the medial or lateral compartments.
- Correction of varus, valgus, or posttraumatic deformity. .
- As an alternative to tibial osteotomy in patients with unicompartmental NIDJD disease. .
- Revision procedures where other treatments or devices have failed. ●

This device is intended for cemented use only.

| Type of Use (Select one or both, as applicable) |
|-------------------------------------------------|
|-------------------------------------------------|

> Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# K232114 - 510(K) SUMMARY

| Submitter's Name:              | Kyocera Medical Technologies, Inc.                                                                                                   |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| Submitter's Address:           | 1200 California Street<br>Suite 210<br>Redlands, California 92374                                                                    |
| Submitter's Telephone:         | (979) 492-6848                                                                                                                       |
| Contact Person:                | Nathan Wright MS, RAC<br>Empirical Technologies<br>1-719-351-0248<br>nwright@empiricaltech.com<br>Image: EMPIRICAL TECHNOLOGIES logo |
| Date Summary was Prepared:     | April 2, 2024                                                                                                                        |
| Trade or Proprietary Name:     | TRIBRID® Unicompartmental Knee System                                                                                                |
| Device Classification Name:    | Prosthesis, Knee, Femorotibial, Non-Constrained, Cemented,<br>Metal/Polymer                                                          |
| Classification & Regulation #: | Class II per 21 CFR §888.3520                                                                                                        |
| Product Code:                  | HSX                                                                                                                                  |
| Classification Panel:          | Orthopedic                                                                                                                           |

## DESCRIPTION OF THE DEVICE SUBJECT TO PREMARKET NOTIFICATION:

KMTI's TRIBRID® Unicompartmental Knee System is a partial knee replacement prostheses intended for application with bone cement. Partial knee replacement components include femoral and tibial components. Femoral baseplates are CoCrMo Alloy while the Tibial implants are Ti6Al4V Alloy. The Tibial bearing inserts are made from Ultra-High Molecular Weight Polyethylene (UHMWPE) variations. Components are available in a variety of designs and size ranges intended for both primary and revision applications.

# INDICATIONS FOR USE

The Kyocera TRIBRID® Unicompartmental Knee System is indicated for use in patients with the following:

- o Painful and disabled knee joint resulting from osteoarthritis, traumatic arthritis, or idiopathic osteonecrosis, of either the medial or lateral compartments.
- Correction of varus, valgus, or posttraumatic deformity. ●
- As an alternative to tibial osteotomy in patients with unicompartmental NIDJD disease. ●
- Revision procedures where other treatments or devices have failed. ●

This device is intended for cemented use only.

# TECHNOLOGICAL CHARACTERISTICS

The subject and predicate devices have nearly identical technological characteristics and the minor differences do not raise any new issues of safety and effectiveness. Specifically, the following characteristics are identical between the subject and predicates:

- Indications for Use
- Materials of manufacture ●
- Structural support mechanism ●

{4}------------------------------------------------

### Predicate Devices

| 510k Number | Trade or Proprietary or<br>Model Name | Manufacturer                                         | Product<br>Code | Type             |
|-------------|---------------------------------------|------------------------------------------------------|-----------------|------------------|
| K190085     | JOUNEY II<br>Unicompartmental Knee    | Smith & Nephew, Inc.                                 | HSX             | Predicate        |
| K183029     | MOTO™ Lateral Partial<br>Knee System  | Medacta International SA                             | HSX             | Reference Device |
| K190122     | Renovis A200 PS Knee<br>System        | Revnovis (now Kyocera<br>Medical Technologies, Inc.) | JWH, OIY        | Reference Device |

## PERFORMANCE DATA

The TRIBRID® Unicompartmental Knee System has been tested in the following test modes:

- Baseplate Fatigue Testing per ASTM F3140-17 ●
- Intrinsic Stability Characteristics
- Modular Disassembly Characteristics per ASTM F1814 and ASTM F2083 ●
- Femoral Component Durability Testing per ASTM F3210-22 ●
- Range of Motion Assessment per ASTM F2083 ●
- Simulated Wear per ISO 14243-3

The results of this non-clinical testing show that the strength of the TRIBRID® Unicompartmental Knee System is sufficient for its intended use and is substantially equivalent to legally marketed predicate devices.

## CONCLUSION

The overall technology characteristics and mechanical performance data lead to the conclusion that the TRIBRID® Unicompartmental Knee System is substantially equivalent to the predicate device.

---

**Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/HSX/K232114](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/HSX/K232114)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com